Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events

Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events

We collected 96 patients who received dual immunotherapy between January 2019 and June 2024, in a 1:1:1 ratio based on PD-L1 expression levels of negative (<1%), medium (1% ≤ PD-L1 ≤ 49%), and high (PD-L1 ≥ 50%). This study evaluates the efficacy and safety of dual immunotherapy in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Luan, Jianqing Hao, Xiaohong Xie, Xinqing Lin, Shuaiying Wang, Baodan Yu, Qingqing Yang, Changchun Wang, Yang Luan, Gang Yang, Hanxiu Lu, Ping Sun, Yunhui Zhang, Nanshan Zhong, Chengzhi Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Dual immunotherapy
immune-related adverse events
survival period
treatment efficacy
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2542068
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2542068

Similar Items